Navigation Links
Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
Date:8/29/2007

Potential Earlier Identification of Toxicity, Efficacy for Pharmaceutical

Developers

REDWOOD CITY, Calif., Aug. 29 /PRNewswire/ -- Codexis, Inc., a private biotechnology company and leading developer of clean manufacturing processes, today announced it has licensed important intellectual property from the California Institute of Technology for preparing and identifying drug metabolites (substances produced during drug metabolism). Codexis will incorporate this technology in development of new R&D productivity tools for use by the pharmaceutical industry.

This technology is based on development of a family of diverse variants of bacterial cytochrome P450 enzymes by Frances Arnold, Ph.D., Dick and Barbara Dickinson Professor of Chemical Engineering and Biochemistry, Cal Tech. Dr. Arnold will join the Codexis Industrial Advisory Board.

"This enzyme family can facilitate identification of safer, more efficacious drugs earlier in the drug development process by expediting the production of potential human metabolites of drug candidates," said Peter Seufer-Wasserthal, Ph.D., Vice President and General Manager, Codexis Pharma Services Group. "Additionally, this technology can be used for lead diversification and complements the human cytochrome biocatalyst products and services at BioCatalytics, acquired by Codexis in July."

"Current metabolite identification and synthesis methods are based on classical chemistry methods, which can be slow and cumbersome," he added. "Combining Codexis' leading position as a developer of biocatalytic products and processes for the pharmaceutical industry with the techniques developed by Dr. Arnold will enable us to provide a powerful, efficient new tool set for rapid identification and synthesis of drug metabolites. These new tools could add considerable value in metabolite profiling as well as lead diversification in drug discovery."

Drug metabolites are produced by the body during the break-down (metabolism) of drugs. Primary metabolites are largely formed in the liver by human P450 enzymes to aid in elimination of a drug from the body. In some cases, metabolites can be toxic, while for other drugs, "active" metabolites have shown improved efficacy and lower toxicity than the administered drug substance. The US Food and Drug Administration now recommends metabolic characterization for all new investigational human therapeutics.

Codexis, Inc. is a leading developer of clean biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. Codexis' proprietary directed evolution technologies enable novel solutions for efficient, cost-effective and environmentally friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the company was recognized by the U.S. EPA with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information please visit http://www.codexis.com

Contact: Justin Jackson, jjackson@burnsmc.com of Burns McClellan, 212-213-0006, or Lyn Christenson, Codexis, lyn.christenson@codexis.com, 650-298-5368.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. Simultaneous Determination of Residues of Approximately 100 Pesticides and Metabolites in Fruit and Vegetables by LC/MS/MS
7. Detection of nitrofurane metabolites in food with HPLC/MS/MS
8. Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS
9. High sensitivity quantitation of metabolites of nitrofuran antibiotics in animal tissue using LC/MS/MS
10. Analysis of Nitrofurans Metabolites by Positive Ion Electrospray LC/MS/MS
11. Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... RADNOR, Pa., Feb. 24, 2017  VWR Corporation (NASDAQ: VWR), ... to laboratory and production customers, today reported its financial results ... 2016. Highlights: 4Q16 record ... up 1.0% on an organic basis. ... on an organic basis, while the Americas net sales increased ...
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
Breaking Biology Technology:
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
Breaking Biology News(10 mins):